- Home
- FENC vs TRVI Comparison
FENC vs TRVI Comparison
Compare FENC & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- TRVI
- Stock Information
- Founded
- FENC 1996
- TRVI 2011
- Country
- FENC United States
- TRVI United States
- Employees
- FENC N/A
- TRVI N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- FENC Health Care
- TRVI Health Care
- Exchange
- FENC Nasdaq
- TRVI Nasdaq
- Market Cap
- FENC 181.7M
- TRVI 211.4M
- IPO Year
- FENC 2001
- TRVI 2019
- Fundamental
- Price
- FENC $3.99
- TRVI $2.75
- Analyst Decision
- FENC Strong Buy
- TRVI Strong Buy
- Analyst Count
- FENC 2
- TRVI 8
- Target Price
- FENC $14.00
- TRVI $9.13
- AVG Volume (30 Days)
- FENC 116.0K
- TRVI 659.5K
- Earning Date
- FENC 11-07-2024
- TRVI 11-06-2024
- Dividend Yield
- FENC N/A
- TRVI N/A
- EPS Growth
- FENC N/A
- TRVI N/A
- EPS
- FENC N/A
- TRVI N/A
- Revenue
- FENC $49,348,000.00
- TRVI N/A
- Revenue This Year
- FENC $116.50
- TRVI N/A
- Revenue Next Year
- FENC $17.49
- TRVI N/A
- P/E Ratio
- FENC N/A
- TRVI N/A
- Revenue Growth
- FENC 278.09
- TRVI N/A
- 52 Week Low
- FENC $3.97
- TRVI $0.97
- 52 Week High
- FENC $11.92
- TRVI $4.00
- Technical
- Relative Strength Index (RSI)
- FENC 38.47
- TRVI 37.52
- Support Level
- FENC $3.99
- TRVI $2.80
- Resistance Level
- FENC $4.57
- TRVI $3.22
- Average True Range (ATR)
- FENC 0.31
- TRVI 0.20
- MACD
- FENC -0.02
- TRVI -0.03
- Stochastic Oscillator
- FENC 2.33
- TRVI 14.68
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.